Raymond Barlow Email & Phone Number

Dublin City, County Dublin, Ie

SynOx Therapeutics Limited is a Dublin, Ireland-based, late-stage clinical biopharmaceutical company developing emactuzumab, a best-in-class monoclonal antibody against CSF-1R, for the treatment of tenosynovial giant cell tumours (TGCT) and other macrophage related disorders. SynOx is led by an experienced team of industry professionals with a successful track record of developing and bringing products to commercialisation. It is backed by a strong syndicate of premier life science investors including HealthCap, Medicxi, Forbion and Gimv. Other shareholders include Celleron Therapeutics and Roche.

Dublin City, County Dublin, Ie

Ikigai Life Sciences Limited is a global consultancy and advisory business focused on the biopharmaceutical industry.

Kiadis is an emerging leader in the Natural Killer (NK) cell therapy space. Kiadis has ongoing clinical trials in oncology and infectious diseases and an international manufacturing base. c.100 staff in EU, US and UK.  Brought on board as the first CBO to lead all strategic and operational business development activities  First project was to ensure completion of a licensing and option agreement with Sanofi on a previously undisclosed pre-clinical K-NK programme: €875 million plus royalties  Multiple ongoing BD processes, including discussion with large Pharma partners  On November 2nd Sanofi announced offer to buy Kiadis for $356 million a 272% premium to the undisturbed share price. Deal successfully closed on April 16th 2021.

London , Gb

ETX is a UK-based drug discovery business with a revolutionary computer-based platform that can rapidly identify new drugs and generate novel and actionable biological insight. I was brought onto the Board to lead the public company turnaround, drive revenue generation and position the business for its future success. Arrested insolvency and developed the business utilising existing capital. Key achievements include: ☛Created and agreed new business strategy and fundamentally refocused internal activities. ☛Completely overhauled branding including new website, commercial videos and presentations.☛Undertook systematic global BD exercise going from zero activity to ultimately win paying commercial customers. ☛Initiated M&A screen, including a number of active processes ☛Guided portfolio rationalisation and innovation reducing 17 cash consumptive projects to 2. ☛Refocused research on commercially relevant projects, now forming foundation of BD discussions. ☛Created a completely new and revolutionary technology (GAINs), now forming basis of BD discussions. ☛Minimised cost/cash consumption reducing loss from £16.8m (inherited) to £5.1m without limiting prospects for the business. ☛Reduced headcount from 27 to 18 while retaining and motivating key group of leaders.☛Drove significant change in investor base through engaging new investors (>30% of register). Delivered international non-deal roadshows in US, EU, China to raise awareness.☛R&D spend reduced from £11m to £3.7m and operating losses from £6.8m to £5.1m between 2016 to 2018. Projects increased from 13 to 27 and commercial deals from 0 to 4 in the same period. ☛Generated first commercial revenues in the company’s history via deals with Novo Nordisk

Thousand Oaks, Ca, Us

• Amgen is a leading multi-national biopharmaceutical business with a mission to serve patients worldwide. $24bn t/o and 19.2k staff. I was hired to create an international corporate development capability and transact deals that delivered on Amgen’s strategy while helping define that strategy. Key achievements include:☛Only ex-US member of the Business Development Senior Leadership Team and member of EU Research and Development Forum.☛Transactional and negotiation expert and global project leader on deals and business change initiatives that supported Amgen’s global business, TA and Regional growth strategies.☛Repatriated 3 important marketed growth products (Prolia, Xgeva and Vectibix) from GSK in existing and emerging markets (Europe, ASIA Pacific, LatAm and MEA). ☛Part of international expansion project. Amgen now has a presence in approximately 100 countries, growing from 50 countries in 2011. Ex-US sales are now 25% ($6bn) of Amgen’s total revenues. ☛Drove acquisition of Dezima Pharmaceuticals to access a Phase 3-ready CV asset.☛Led re-acquisition of AMG420 a phase 1 BCMA BiTe for haematology/oncology.☛Delivered US commercialisation deal with Novartis on AIMOVIG, a first-in-class migraine product. Won ‘launch of the year 2018’.

New Brunswick, Nj, Us

Crucell was a biotechnology company acquired by J&J in 2010 taking its stake to 95% by early-2011. I was recruited into Crucell to professionalize the BD function, drive activities and to execute a major merger, acquisition or trade sale. I was responsible for BD projects across all areas of the business including: corporate (M&A and licensing); global product management; global marketing and sales; global development; global operations; supply chain; and Innovation & Discovery. Key achievements include:☛Led an acquisition project on a $bn EU biotechnology company☛Senior member of the BD team responsible for presenting the Crucell business to J&J, orchestrating the due diligence exercise and the sale process, leading to the acquisition of the company for $2.4bn (~60% premium).☛Post-acquisition took responsibility for immunotherapy BD area for J&J and for licensing activities for vaccine and infectious disease Innovation & Discovery.☛Special leadership and operational responsibility for global influenza vaccine business including formulating the global business strategy, a key driver for the JNJ acquisition.☛Completed multiple in-licensing, option and collaboration deals ranging from university option deals to long-term supply agreements which secured the future of vaccines Inflexal V© and Epaxal©.

I established, developed and managed this internationally-focused consultancy business. Projects included: ☛Interim CEO of Asterion Ltd for 18 months (www.asterion.co.uk) overhauling the business. Secured $1.5M in new funding, closed license and option deals with Ipsen and Genzyme. Also delivered a binding series A investment term sheet of $12m from new investors.☛Lead advisor on major transformational acquisition for an EU Biotechnology major.☛Out-licensing of an FDA and EMEA approved product in selected countries on a global basis.☛EU country entry and product launch projects for a US Biotechnology company.☛Commercial and competitive strategy project for a Belgian Biotechnology company.☛Key in-licensing project for a Pharma major.☛EU country launch strategy for Japanese major, including marketing plans and sales force infrastructure.☛Product acquisition and service-based medical technology project for UK Marketing company.☛Head of Business Development projects for UK Biotechnology company.☛Identified targets and valued potential investment portfolio for Middle Eastern Investor Group.☛Renegotiation of manufacturing and supply Agreements in China for UK Biotechnology company.

Gaithersburg, Maryland, Us

• Brought into business by investors to achieve trade sale and partner assets to large pharma.

Cambridge, Cambridgeshire, Gb

Cambridge, Cambridgeshire, Gb

Cambridge, Cambridgeshire, Gb

Cambridge, Cambridgeshire, Gb

Cambridge, Cambridgeshire, Gb

Master Of Business Administration (M.B.A.), Mba

Phd, Chemistry

Bachelor Of Science (Bsc), Chemistry